Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca has pulled Andexxa AstraZeneca has pulled its anticoagulant therapy, Andexxa (recombinant coagulation factor Xa), from ...

After a postmarketing study of AstraZeneca's bleeding reversal agent Andexxa met its primary endpoint earlier than planned, AZ is ending the study at the recommendation of a data monitoring board. In ...

On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc’s (NASDAQ:AZN) supplemental biologics license application for Andexxa (coagulation factor Xa ...

FDA-approved Andexxa reversed Xarelto and Eliquis bleeding but was linked to higher rates of blood clots and death, raising serious patient safety concerns Andexxa was marketed as the solution to stop ...

ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care AstraZeneca to proceed with regulatory filings to convert from conditional to full ...